Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.
An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
A class Ia antiarrhythmic drug that is structurally-related to PROCAINE.
A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.
Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.
An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.
A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.
An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.
A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.
Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY.
An abnormally rapid ventricular rhythm usually in excess of 150 beats per minute. It is generated within the ventricle below the BUNDLE OF HIS, either as autonomic impulse formation or reentrant impulse conduction. Depending on the etiology, onset of ventricular tachycardia can be paroxysmal (sudden) or nonparoxysmal, its wide QRS complexes can be uniform or polymorphic, and the ventricular beating may be independent of the atrial beating (AV dissociation).
A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.
An antiarrhythmic agent which exerts a potential- and frequency-dependent block of SODIUM CHANNELS.
A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness (SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST.
Removal of tissue with electrical current delivered via electrodes positioned at the distal end of a catheter. Energy sources are commonly direct current (DC-shock) or alternating current at radiofrequencies (usually 750 kHz). The technique is used most often to ablate the AV junction and/or accessory pathways in order to interrupt AV conduction and produce AV block in the treatment of various tachyarrhythmias.
Rapid, irregular atrial contractions caused by a block of electrical impulse conduction in the right atrium and a reentrant wave front traveling up the inter-atrial septum and down the right atrial free wall or vice versa. Unlike ATRIAL FIBRILLATION which is caused by abnormal impulse generation, typical atrial flutter is caused by abnormal impulse conduction. As in atrial fibrillation, patients with atrial flutter cannot effectively pump blood into the lower chambers of the heart (HEART VENTRICLES).
Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia.
A group of compounds that are derivatives of beta- aminoethylbenzene which is structurally and pharmacologically related to amphetamine. (From Merck Index, 11th ed)
A class Ib anti-arrhythmia agent used to manage ventricular and supraventricular arrhythmias.
An impulse-conducting system composed of modified cardiac muscle, having the power of spontaneous rhythmicity and conduction more highly developed than the rest of the heart.
A group of cardiac arrhythmias in which the cardiac contractions are not initiated at the SINOATRIAL NODE. They include both atrial and ventricular premature beats, and are also known as extra or ectopic heartbeats. Their frequency is increased in heart diseases.
The period of time following the triggering of an ACTION POTENTIAL when the CELL MEMBRANE has changed to an unexcitable state and is gradually restored to the resting (excitable) state. During the absolute refractory period no other stimulus can trigger a response. This is followed by the relative refractory period during which the cell gradually becomes more excitable and the stronger impulse that is required to illicit a response gradually lessens to that required during the resting state.
The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065)
The chambers of the heart, to which the BLOOD returns from the circulation.
Abrupt changes in the membrane potential that sweep along the CELL MEMBRANE of excitable cells in response to excitation stimuli.
The veins that return the oxygenated blood from the lungs to the left atrium of the heart.
An electrical current applied to the HEART to terminate a disturbance of its rhythm, ARRHYTHMIAS, CARDIAC. (Stedman, 25th ed)
A class of drugs that act by inhibition of sodium influx through cell membranes. Blockade of sodium channels slows the rate and amplitude of initial rapid depolarization, reduces cell excitability, and reduces conduction velocity.
The study of the generation and behavior of electrical charges in living organisms particularly the nervous system and the effects of electricity on living organisms.
The hollow, muscular organ that maintains the circulation of the blood.
One of the ANTI-ARRHYTHMIA AGENTS, it blocks VOLTAGE-GATED SODIUM CHANNELS and slows conduction within the His-Purkinje system and MYOCARDIUM.
Compounds based on N-phenylacetamide, that are similar in structure to 2-PHENYLACETAMIDES. They are precursors of many other compounds. They were formerly used as ANALGESICS and ANTIPYRETICS, but often caused lethal METHEMOGLOBINEMIA.
A C19 norditerpenoid alkaloid (DITERPENES) from the root of ACONITUM plants. It activates VOLTAGE-GATED SODIUM CHANNELS. It has been used to induce ARRHYTHMIAS in experimental animals and it has antiinflammatory and antineuralgic properties.
Regulation of the rate of contraction of the heart muscles by an artificial pacemaker.
A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research.
A class of drugs that act by inhibition of potassium efflux through cell membranes. Blockade of potassium channels prolongs the duration of ACTION POTENTIALS. They are used as ANTI-ARRHYTHMIA AGENTS and VASODILATOR AGENTS.
Glycosides from plants of the genus DIGITALIS. Some of these are useful as cardiotonic and anti-arrhythmia agents. Included also are semi-synthetic derivatives of the naturally occurring glycosides. The term has sometimes been used more broadly to include all CARDIAC GLYCOSIDES, but here is restricted to those related to Digitalis.
An alkaloid found in the root of RAUWOLFIA SERPENTINA, among other plant sources. It is a class Ia antiarrhythmic agent that apparently acts by changing the shape and threshold of cardiac action potentials.
The number of times the HEART VENTRICLES contract per unit of time, usually per minute.
An antiarrhythmia agent used primarily for ventricular rhythm disturbances.
Ion channels that specifically allow the passage of SODIUM ions. A variety of specific sodium channel subtypes are involved in serving specialized functions such as neuronal signaling, CARDIAC MUSCLE contraction, and KIDNEY function.
A generic expression for any tachycardia that originates above the BUNDLE OF HIS.
Cell membrane glycoproteins that are selectively permeable to potassium ions. At least eight major groups of K channels exist and they are made up of dozens of different subunits.
A genus of toxic herbaceous Eurasian plants of the Plantaginaceae which yield cardiotonic DIGITALIS GLYCOSIDES. The most useful species are Digitalis lanata and D. purpurea.
The lower right and left chambers of the heart. The right ventricle pumps venous BLOOD into the LUNGS and the left ventricle pumps oxygenated blood into the systemic arterial circulation.
A malignant form of polymorphic ventricular tachycardia that is characterized by HEART RATE between 200 and 250 beats per minute, and QRS complexes with changing amplitude and twisting of the points. The term also describes the syndrome of tachycardia with prolonged ventricular repolarization, long QT intervals exceeding 500 milliseconds or BRADYCARDIA. Torsades de pointes may be self-limited or may progress to VENTRICULAR FIBRILLATION.
Implantable devices which continuously monitor the electrical activity of the heart and automatically detect and terminate ventricular tachycardia (TACHYCARDIA, VENTRICULAR) and VENTRICULAR FIBRILLATION. They consist of an impulse generator, batteries, and electrodes.
Conical muscular projections from the walls of the cardiac ventricles, attached to the cusps of the atrioventricular valves by the chordae tendineae.
A family of hexahydropyridines.
Method in which prolonged electrocardiographic recordings are made on a portable tape recorder (Holter-type system) or solid-state device ("real-time" system), while the patient undergoes normal daily activities. It is useful in the diagnosis and management of intermittent cardiac arrhythmias and transient myocardial ischemia.
Methods to induce and measure electrical activities at specific sites in the heart to diagnose and treat problems with the heart's electrical system.
The return of a sign, symptom, or disease after a remission.
Modified cardiac muscle fibers composing the terminal portion of the heart conduction system.
A group of compounds that contain the structure SO2NH2.
A type of cardiac arrhythmia with premature contractions of the HEART VENTRICLES. It is characterized by the premature QRS complex on ECG that is of abnormal shape and great duration (generally >129 msec). It is the most common form of all cardiac arrhythmias. Premature ventricular complexes have no clinical significance except in concurrence with heart diseases.
Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.
A calcium channel blocker that is a class IV anti-arrhythmia agent.
Abnormally rapid heartbeats with sudden onset and cessation.
A family of voltage-gated potassium channels that are characterized by long N-terminal and C-terminal intracellular tails. They are named from the Drosophila protein whose mutation causes abnormal leg shaking under ether anesthesia. Their activation kinetics are dependent on extracellular MAGNESIUM and PROTON concentration.
A small nodular mass of specialized muscle fibers located in the interatrial septum near the opening of the coronary sinus. It gives rise to the atrioventricular bundle of the conduction system of the heart.
AMINO ALCOHOLS containing the propanolamine (NH2CH2CHOHCH2) group and its derivatives.
The circulation in a portion of the body of one individual of blood supplied from another individual.
Compounds based on reduced IMIDAZOLINES which contain no double bonds in the ring.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
A derivative of the rauwolfia alkaloid AJMALINE. It is an anti-arrhythmia agent, but may cause liver damage.
A type of cardiac arrhythmia with premature atrial contractions or beats caused by signals originating from ectopic atrial sites. The ectopic signals may or may not conduct to the HEART VENTRICLES. Atrial premature complexes are characterized by premature P waves on ECG which are different in configuration from the P waves generated by the normal pacemaker complex in the SINOATRIAL NODE.
The relationship between the dose of an administered drug and the response of the organism to the drug.
The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow.
Abnormally rapid heartbeats originating from one or more automatic foci (nonsinus pacemakers) in the HEART ATRIUM but away from the SINOATRIAL NODE. Unlike the reentry mechanism, automatic tachycardia speeds up and slows down gradually. The episode is characterized by a HEART RATE between 135 to less than 200 beats per minute and lasting 30 seconds or longer.
Potassium channel whose permeability to ions is extremely sensitive to the transmembrane potential difference. The opening of these channels is induced by the membrane depolarization of the ACTION POTENTIAL.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).
A group of compounds that are derivatives of methoxybenzene and contain the general formula R-C7H7O.
Unexpected rapid natural death due to cardiovascular collapse within one hour of initial symptoms. It is usually caused by the worsening of existing heart diseases. The sudden onset of symptoms, such as CHEST PAIN and CARDIAC ARRHYTHMIAS, particularly VENTRICULAR TACHYCARDIA, can lead to the loss of consciousness and cardiac arrest followed by biological death. (from Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed., 2005)
Dibenzoquinolines derived in plants from (S)-reticuline (BENZYLISOQUINOLINES).
A class of drugs that act by selective inhibition of calcium influx through cellular membranes.
A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.
The small mass of modified cardiac muscle fibers located at the junction of the superior vena cava (VENA CAVA, SUPERIOR) and right atrium. Contraction impulses probably start in this node, spread over the atrium (HEART ATRIUM) and are then transmitted by the atrioventricular bundle (BUNDLE OF HIS) to the ventricle (HEART VENTRICLE).
A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
Elements of limited time intervals, contributing to particular results or situations.
A delayed rectifier subtype of shaker potassium channels that conducts a delayed rectifier current. It contributes to ACTION POTENTIAL repolarization of MYOCYTES in HEART ATRIA.
A surface anesthetic that acts by preventing transmission of impulses along NERVE FIBERS and at NERVE ENDINGS.
Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666)
Compounds possessing both a hydroxyl (-OH) and an amino group (-NH2).
The study of the electrical activity and characteristics of the HEART; MYOCARDIUM; and CARDIOMYOCYTES.
The hemodynamic and electrophysiological action of the HEART ATRIA.
A rare form of supraventricular tachycardia caused by automatic, not reentrant, conduction initiated from sites at the atrioventricular junction, but not the ATRIOVENTRICULAR NODE. It usually occurs during myocardial infarction, after heart surgery, or in digitalis intoxication with a HEART RATE ranging from 140 to 250 beats per minute.
Striated muscle cells found in the heart. They are derived from cardiac myoblasts (MYOBLASTS, CARDIAC).
Contractile activity of the MYOCARDIUM.
Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
Damage to the MYOCARDIUM resulting from MYOCARDIAL REPERFUSION (restoration of blood flow to ischemic areas of the HEART.) Reperfusion takes place when there is spontaneous thrombolysis, THROMBOLYTIC THERAPY, collateral flow from other coronary vascular beds, or reversal of vasospasm.
A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures.
A class of drugs that stimulate sodium influx through cell membrane channels.
Compounds containing dibenzo-1,4-thiazine. Some of them are neuroactive.
Small band of specialized CARDIAC MUSCLE fibers that originates in the ATRIOVENTRICULAR NODE and extends into the membranous part of the interventricular septum. The bundle of His, consisting of the left and the right bundle branches, conducts the electrical impulses to the HEART VENTRICLES in generation of MYOCARDIAL CONTRACTION.
An electrophysiologic technique for studying cells, cell membranes, and occasionally isolated organelles. All patch-clamp methods rely on a very high-resistance seal between a micropipette and a membrane; the seal is usually attained by gentle suction. The four most common variants include on-cell patch, inside-out patch, outside-out patch, and whole-cell clamp. Patch-clamp methods are commonly used to voltage clamp, that is control the voltage across the membrane and measure current flow, but current-clamp methods, in which the current is controlled and the voltage is measured, are also used.
Injections made into a vein for therapeutic or experimental purposes.
The active sympathomimetic hormone from the ADRENAL MEDULLA. It stimulates both the alpha- and beta- adrenergic systems, causes systemic VASOCONSTRICTION and gastrointestinal relaxation, stimulates the HEART, and dilates BRONCHI and cerebral vessels. It is used in ASTHMA and CARDIAC FAILURE and to delay absorption of local ANESTHETICS.
Application of a ligature to tie a vessel or strangulate a part.
NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
Compounds that contain a BENZENE ring fused to a furan ring.
A class of saturated compounds consisting of two rings only, having two or more atoms in common, containing at least one hetero atom, and that take the name of an open chain hydrocarbon containing the same total number of atoms. (From Riguady et al., Nomenclature of Organic Chemistry, 1979, p31)
The voltage differences across a membrane. For cellular membranes they are computed by subtracting the voltage measured outside the membrane from the voltage measured inside the membrane. They result from differences of inside versus outside concentration of potassium, sodium, chloride, and other ions across cells' or ORGANELLES membranes. For excitable cells, the resting membrane potentials range between -30 and -100 millivolts. Physical, chemical, or electrical stimuli can make a membrane potential more negative (hyperpolarization), or less negative (depolarization).
Chemical substances with sperm immobilizing activity used as topically administered vaginal contraceptives.
Cardiac arrhythmias that are characterized by excessively slow HEART RATE, usually below 50 beats per minute in human adults. They can be classified broadly into SINOATRIAL NODE dysfunction and ATRIOVENTRICULAR BLOCK.
The use of freezing as a special surgical technique to destroy or excise tissue.
A conical fibro-serous sac surrounding the HEART and the roots of the great vessels (AORTA; VENAE CAVAE; PULMONARY ARTERY). Pericardium consists of two sacs: the outer fibrous pericardium and the inner serous pericardium. The latter consists of an outer parietal layer facing the fibrous pericardium, and an inner visceral layer (epicardium) resting next to the heart, and a pericardial cavity between these two layers.
The veins and arteries of the HEART.
A device designed to stimulate, by electric impulses, contraction of the heart muscles. It may be temporary (external) or permanent (internal or internal-external).
Use of electric potential or currents to elicit biological responses.
A semisynthetic digitalis glycoside with the general properties of DIGOXIN but more rapid onset of action. Its cardiotonic action is prolonged by its demethylation to DIGOXIN in the liver. It has been used in the treatment of congestive heart failure (HEART FAILURE).
A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS.
Drugs that bind to but do not activate ADRENERGIC RECEPTORS. Adrenergic antagonists block the actions of the endogenous adrenergic transmitters EPINEPHRINE and NOREPINEPHRINE.
The hemodynamic and electrophysiological action of the HEART VENTRICLES.
Impaired conduction of cardiac impulse that can occur anywhere along the conduction pathway, such as between the SINOATRIAL NODE and the right atrium (SA block) or between atria and ventricles (AV block). Heart blocks can be classified by the duration, frequency, or completeness of conduction block. Reversibility depends on the degree of structural or functional defects.
A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE.
A group of slow opening and closing voltage-gated potassium channels. Because of their delayed activation kinetics they play an important role in controlling ACTION POTENTIAL duration.
The species Oryctolagus cuniculus, in the family Leporidae, order LAGOMORPHA. Rabbits are born in burrows, furless, and with eyes and ears closed. In contrast with HARES, rabbits have 22 chromosome pairs.
Connections between cells which allow passage of small molecules and electric current. Gap junctions were first described anatomically as regions of close apposition between cells with a narrow (1-2 nm) gap between cell membranes. The variety in the properties of gap junctions is reflected in the number of CONNEXINS, the family of proteins which form the junctions.
Cessation of heart beat or MYOCARDIAL CONTRACTION. If it is treated within a few minutes, heart arrest can be reversed in most cases to normal cardiac rhythm and effective circulation.
A form of ventricular pre-excitation characterized by a short PR interval and a long QRS interval with a delta wave. In this syndrome, atrial impulses are abnormally conducted to the HEART VENTRICLES via an ACCESSORY CONDUCTING PATHWAY that is located between the wall of the right or left atria and the ventricles, also known as a BUNDLE OF KENT. The inherited form can be caused by mutation of PRKAG2 gene encoding a gamma-2 regulatory subunit of AMP-activated protein kinase.
PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS.
A voltage-gated sodium channel subtype that mediates the sodium ion PERMEABILITY of CARDIOMYOCYTES. Defects in the SCN5A gene, which codes for the alpha subunit of this sodium channel, are associated with a variety of CARDIAC DISEASES that result from loss of sodium channel function.
The family of steroids from which the androgens are derived.
Drugs that block nerve conduction when applied locally to nerve tissue in appropriate concentrations. They act on any part of the nervous system and on every type of nerve fiber. In contact with a nerve trunk, these anesthetics can cause both sensory and motor paralysis in the innervated area. Their action is completely reversible. (From Gilman AG, et. al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed) Nearly all local anesthetics act by reducing the tendency of voltage-dependent sodium channels to activate.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Abnormally rapid heartbeats caused by reentry of atrial impulse into the dual (fast and slow) pathways of ATRIOVENTRICULAR NODE. The common type involves a blocked atrial impulse in the slow pathway which reenters the fast pathway in a retrograde direction and simultaneously conducts to the atria and the ventricles leading to rapid HEART RATE of 150-250 beats per minute.
Membrane proteins whose primary function is to facilitate the transport of positively charged molecules (cations) across a biological membrane.
Compounds based on benzeneacetamide, that are similar in structure to ACETANILIDES.
A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. NITROUS OXIDE is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required. (From AMA Drug Evaluations Annual, 1994, p178)
A plant species of the genus CITRUS, family RUTACEAE that produces the familiar grapefruit. There is evidence that grapefruit inhibits CYTOCHROME P-450 CYP3A4, resulting in delayed metabolism and higher blood levels of a variety of drugs.
Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.
A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed)
A condition in which HEART VENTRICLES exhibit impaired function.
An element in the alkali group of metals with an atomic symbol K, atomic number 19, and atomic weight 39.10. It is the chief cation in the intracellular fluid of muscle and other cells. Potassium ion is a strong electrolyte that plays a significant role in the regulation of fluid volume and maintenance of the WATER-ELECTROLYTE BALANCE.
The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed)
3 beta,5,14-Trihydroxy-19-oxo-5 beta-card-20(22)-enolide. The aglycone cardioactive agent isolated from Strophanthus Kombe, S. gratus and other species; it is a very toxic material formerly used as digitalis. Synonyms: Apocymarin; Corchorin; Cynotoxin; Corchorgenin.
The decrease in a measurable parameter of a PHYSIOLOGICAL PROCESS, including cellular, microbial, and plant; immunological, cardiovascular, respiratory, reproductive, urinary, digestive, neural, musculoskeletal, ocular, and skin physiological processes; or METABOLIC PROCESS, including enzymatic and other pharmacological processes, by a drug or other chemical.
Compounds with a core of fused benzo-pyran rings.
The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM.
The innermost layer of the heart, comprised of endothelial cells.
An antagonist of histamine H1 receptors.
A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.
An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs.
Inorganic or organic compounds derived from phosphine (PH3) by the replacement of H atoms. (From Grant & Hackh's Chemical Dictionary, 5th ed)
Derivatives of ammonium compounds, NH4+ Y-, in which all four of the hydrogens bonded to nitrogen have been replaced with hydrocarbyl groups. These are distinguished from IMINES which are RN=CR2.
A 43-kDa peptide which is a member of the connexin family of gap junction proteins. Connexin 43 is a product of a gene in the alpha class of connexin genes (the alpha-1 gene). It was first isolated from mammalian heart, but is widespread in the body including the brain.
Compounds containing phenyl-1-butanone.
A guanidine that opens POTASSIUM CHANNELS producing direct peripheral vasodilatation of the ARTERIOLES. It reduces BLOOD PRESSURE and peripheral resistance and produces fluid retention. (Martindale The Extra Pharmacopoeia, 31st ed)
A plant genus of the family RANUNCULACEAE. Members contain a number of diterpenoid alkaloids including: aconitans, hypaconitine, ACONITINE, jesaconitine, ignavine, napelline, and mesaconitine. The common name of Wolfbane is similar to the common name for ARNICA.
Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.
The electrical properties, characteristics of living organisms, and the processes of organisms or their parts that are involved in generating and responding to electrical charges.
The action of a drug that may affect the activity, metabolism, or toxicity of another drug.
A form of heart block in which the electrical stimulation of HEART VENTRICLES is interrupted at either one of the branches of BUNDLE OF HIS thus preventing the simultaneous depolarization of the two ventricles.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
A group of fatty acids, often of marine origin, which have the first unsaturated bond in the third position from the omega carbon. These fatty acids are believed to reduce serum triglycerides, prevent insulin resistance, improve lipid profile, prolong bleeding times, reduce platelet counts, and decrease platelet adhesiveness.
A family of fused-ring hydrocarbons isolated from coal tar that act as intermediates in various chemical reactions and are used in the production of coumarone-indene resins.
Transmission of the readings of instruments to a remote location by means of wires, radio waves, or other means. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
Long-lasting voltage-gated CALCIUM CHANNELS found in both excitable and nonexcitable tissue. They are responsible for normal myocardial and vascular smooth muscle contractility. Five subunits (alpha-1, alpha-2, beta, gamma, and delta) make up the L-type channel. The alpha-1 subunit is the binding site for calcium-based antagonists. Dihydropyridine-based calcium antagonists are used as markers for these binding sites.
A major metabolite of PROCAINAMIDE. Its anti-arrhythmic action may cause cardiac toxicity in kidney failure.
10-carbon saturated monocarboxylic acids.
The functions and activities of living organisms or their parts involved in generating and responding to electrical charges .
Organic compounds containing both the hydroxyl and carboxyl radicals.
The abrupt cessation of all vital bodily functions, manifested by the permanent loss of total cerebral, respiratory, and cardiovascular functions.
A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain.
An agent that blocks the release of adrenergic transmitters and may have other actions. It was formerly used as an antihypertensive agent, but is now proposed as an anti-arrhythmic.
Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE).
ISOQUINOLINES with a benzyl substituent.
Electrodes with an extremely small tip, used in a voltage clamp or other apparatus to stimulate or record bioelectric potentials of single cells intracellularly or extracellularly. (Dorland, 28th ed)
The process of observing, recording, or detecting the effects of a chemical substance administered to an individual therapeutically or diagnostically.
The giving of drugs, chemicals, or other substances by mouth.
A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
A group of compounds that are derivatives of oxo-pyrrolidines. A member of this group is 2-oxo pyrrolidine, which is an intermediate in the manufacture of polyvinylpyrrolidone. (From Merck Index, 11th ed)
Recording of regional electrophysiological information by analysis of surface potentials to give a complete picture of the effects of the currents from the heart on the body surface. It has been applied to the diagnosis of old inferior myocardial infarction, localization of the bypass pathway in Wolff-Parkinson-White syndrome, recognition of ventricular hypertrophy, estimation of the size of a myocardial infarct, and the effects of different interventions designed to reduce infarct size. The limiting factor at present is the complexity of the recording and analysis, which requires 100 or more electrodes, sophisticated instrumentation, and dedicated personnel. (Braunwald, Heart Disease, 4th ed)
Generally, restoration of blood supply to heart tissue which is ischemic due to decrease in normal blood supply. The decrease may result from any source including atherosclerotic obstruction, narrowing of the artery, or surgical clamping. Reperfusion can be induced to treat ischemia. Methods include chemical dissolution of an occluding thrombus, administration of vasodilator drugs, angioplasty, catheterization, and artery bypass graft surgery. However, it is thought that reperfusion can itself further damage the ischemic tissue, causing MYOCARDIAL REPERFUSION INJURY.
Agents that are capable of inducing a total or partial loss of sensation, especially tactile sensation and pain. They may act to induce general ANESTHESIA, in which an unconscious state is achieved, or may act locally to induce numbness or lack of sensation at a targeted site.
A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
Batrachotoxin is the 20-alpha-bromobenzoate of batrachotoxin A; they are toxins from the venom of a small Colombian frog, Phyllobates aurotaenia, cause release of acetylcholine, destruction of synaptic vesicles and depolarization of nerve and muscle fibers.
A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
A derivative of the NIACINAMIDE that is structurally combined with an organic nitrate. It is a potassium-channel opener that causes vasodilatation of arterioles and large coronary arteries. Its nitrate-like properties produce venous vasodilation through stimulation of guanylate cyclase.
Treatment process involving the injection of fluid into an organ or tissue.
A quinolizidine alkaloid isolated from several FABACEAE including LUPINUS; SPARTIUM; and CYTISUS. It has been used as an oxytocic and an anti-arrhythmia agent. It has also been of interest as an indicator of CYP2D6 genotype.
A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME.
An autosomal dominant defect of cardiac conduction that is characterized by an abnormal ST-segment in leads V1-V3 on the ELECTROCARDIOGRAM resembling a right BUNDLE-BRANCH BLOCK; high risk of VENTRICULAR TACHYCARDIA; or VENTRICULAR FIBRILLATION; SYNCOPAL EPISODE; and possible sudden death. This syndrome is linked to mutations of gene encoding the cardiac SODIUM CHANNEL alpha subunit.
A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment.
An alkaloid from Hydrastis canadensis L., Berberidaceae. It is also found in many other plants. It is relatively toxic parenterally, but has been used orally for various parasitic and fungal infections and as antidiarrheal.
Theoretical representations that simulate the behavior or activity of the cardiovascular system, processes, or phenomena; includes the use of mathematical equations, computers and other electronic equipment.
Gated, ion-selective glycoproteins that traverse membranes. The stimulus for ION CHANNEL GATING can be due to a variety of stimuli such as LIGANDS, a TRANSMEMBRANE POTENTIAL DIFFERENCE, mechanical deformation or through INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS.
This led to research for a new antiarrhythmic drug. As a result, procaine was discovered, which has similar cardiac effects as ... Procainamide works as an anti-arrhythmic agent and is used to treat cardiac arrhythmia. It induces rapid block of the ... Procainamide is a medication of the antiarrhythmic class used for the treatment of cardiac arrhythmias. It is classified by the ... This mechanism is responsible for the antiarrhythmic effect. However, due to the short duration of action, caused by rapid ...
Anti-Arrhythmic Drugs. Hurst's The Heart, Chapter 38. Mechanisms of Cardiac Arrhythmias and Conduction Disturbances. In V. ...
It is a class II antiarrhythmic. Esmolol decreases the force and rate of heart contractions by blocking beta-adrenergic ... Jaillon P, Drici M (December 1989). "Recent antiarrhythmic drugs". The American Journal of Cardiology. 64 (20): 65J-69J. doi: ...
Singh, BN; Vaughan Williams, EM (August 1970). "A third class of anti-arrhythmic action. Effects on atrial and ventricular ... There, he worked on the anti-arrhythmic properties of drugs including amiodarone. Such work helped to refine the ... Nattel, S (26 November 1993). "Comparative mechanisms of action of antiarrhythmic drugs". The American Journal of Cardiology. ... Nattel, S (May 1991). "Antiarrhythmic drug classifications. A critical appraisal of their history, present status, and clinical ...
... is an antiarrhythmic medication of the class Ib type. This means it works by blocking sodium channels and thus ... "Lidocaine Hydrochloride (Antiarrhythmic)". The American Society of Health-System Pharmacists. Archived from the original on ... Lidocaine is also the most important class-1b antiarrhythmic drug; it is used intravenously for the treatment of ventricular ... Sheu SS, Lederer WJ (Oct 1985). "Lidocaine's negative inotropic and antiarrhythmic actions. Dependence on shortening of action ...
... (Tonocard) is a class Ib antiarrhythmic agent. It is no longer sold in the United States. Tocainide is a lidocaine ... October 1979). "New antiarrhythmic agents. 1. Primary alpha-amino anilides". Journal of Medicinal Chemistry. 22 (10): 1171-6. ... GB 1461602, "Primary Amino Acylanilides Methods of Making the Same and Use as Antiarrhythmic Drugs", issued 1974, assigned to ...
Benrixate, an antiarrhythmic agent. Ifenprodil & Ro-25-6981 (MI-4) TCS 46b ASS234 JTV-519 JX-401 KW 4099 [141364-05-8] 2- ...
Joshi GS, Burnett JC, Abraham DJ (2003). "Cardiac Drugs: Antianginal, Vasodilators, Antiarrhythmic". In Abraham DJ (ed.). ...
Antiarrhythmic Drugs: A Practical Guide. 2 ed, 2007 Electrophysiologic Testing. 4 ed, 2006 Fixing American Healthcare: ...
Yoshidomi M, Sukamoto T, Morita T, Ito K, Nose T (1982). "Antiarrhythmic effect of KB-944, a new calcium antagonist. A ... It has antihypertensive and antiarrhythmic effects. Treatment of benzanilide with phosphorus pentasulfide or Lawesson's reagent ...
It is a class IV antiarrhythmic. Diltiazem was approved for medical use in the United States in 1982. It is available as a ...
... - antiarrhythmic drugs". Archived from the original on August 23, 2007. Retrieved 2008-08-27. CS1 maint: ... These trials include the Cardiac Arrhythmia Suppression Trial (CAST), the Antiarrhythmics Versus Implantable Defibrillators ( ... the reduction in use of certain antiarrhythmic agents. Wyse obtained his PhD in Pharmacology in 1969 from McGill University in ... "New insights into the definition and meaning of proarrhythmia during initiation of antiarrhythmic drug therapy from the Cardiac ...
Thus, some antiarrhythmic drugs associated with increased mortality can reduce HRV. However, it is not known whether these ... Data exist for several antiarrhythmic drugs. Flecainide and propafenone but not amiodarone were reported to decrease time ...
Hattori Y, Hidaka T, Aisaka K, Satoh F, Ishihara T (April 1988). "Effect of SUN 1165, a new potent antiarrhythmic agent, on the ... Hattori Y, Inomata N (April 1992). "Modes of the Na channel blocking action of pilsicainide, a new antiarrhythmic agent, in ... Pilsicainide (INN) is an antiarrhythmic agent. It is marketed in Japan as サンリズム (Sunrythm). It was developed by Suntory ... Inomata N, Ishihara T, Akaike N (1987). "SUN 1165: a new antiarrhythmic Na current blocker in ventricular myocytes of guinea- ...
Its therapeutic range for an anticonvulsant effect is 10-20 μg/mL and for an antiarrhythmic effect 10-20 μg/mL. Avoid giving ... It is a class 1b antiarrhythmic. Digoxin toxicity: Intravenous formulation is drug of choice for arrhythmias caused by cardiac ... may be used in the treatment of ventricular tachycardia and sudden episodes of atrial tachycardia after other antiarrhythmic ...
Ferro G, Chiariello M, Tari MG, Vigorito C, Ungaro B, Condorelli M (May 1983). "Intropic effects of several antiarrhythmic ... Bunaftine (or bunaphtine) is an antiarrhythmic agent. It is classified in class III. Tamargo J (August 1980). " ...
"Chapter 5: Antiarrhythmic and Antianginal Agents". In Clarke FH (ed.). Annual Reports in Medicinal Chemistry. 12. Elsevier ...
Returning home he developed new models for the assessment of antiarrhythmic action, which were soon widely applied. He also ... The results and data on experimental cardiac arrhythmias and antiarrhythmic drugs were summarized with his co-authorship in the ... Walker.M.J.A. Antiarrhythmic Drug Research. Br, J, Pharmacol :2006, 147: S222-S231 Achievements of Professor Emeritus László ... He became interested in experimental cardiac arrhythmia and antiarrhythmic drugs, area rather unexplored at that time. Worked ...
... electrophysiologic and antiarrhythmic activity in humans". Journal of Cardiovascular Pharmacology. 15 (1): 144-9. doi:10.1097/ ...
... is an antiarrhythmic beta adrenergic antagonist. Koytchev, R; Alken, RG; Mayer, O; Smith, I; Greenwood, M (1996). " ... "Influence of food on the bioavailability and some pharmacokinetic parameters of diprafenone--a novel antiarrhythmic agent". ...
Reiffel JA, McDonald A (August 2006). "Antiarrhythmic effects of omega-3 fatty acids". The American Journal of Cardiology. 98 ( ...
Lacerda AE, Kuryshev YA, Yan GX, Waldo AL, Brown AM (March 2010). "Vanoxerine: cellular mechanism of a new antiarrhythmic". ... that was in the midst of recruiting participants for a phase III human clinical trial for its use as a cardiac antiarrhythmic ...
It is not FDA approved for human use as an antiarrhythmic agent, and it is not included in the Vaughan Williams classification ... Sparteine is a class 1a antiarrhythmic agent; a sodium channel blocker. It is an alkaloid and can be extracted from scotch ... of antiarrhythmic drugs. It is also used as a chiral ligand in organic chemistry, especially in syntheses involving ...
As with all other antiarrhythmic agents, there is a risk of proarrhythmia associated with the use of flecainide. This risk is ... Flecainide is a class Ic antiarrhythmic agent. It works by decreasing the entry of sodium in heart cells, causing prolongation ... As with all class I antiarrhythmic agents, Flecainide increases the capture thresholds of pacemakers. Due to the narrow ... Morganroth J (1992). "Early and late proarrhythmia from antiarrhythmic drug therapy". Cardiovasc Drugs Ther. 6 (1): 11-14. doi: ...
... and Antiarrhythmic Actions", Antiarrhythmic Drugs: Mechanisms of Antiarrhythmic and Proarrhythmic Actions, Springer Berlin ... Ibutilide is the only antiarrhythmic agent currently approved by the Food and Drug Administration for acute conversion of ... Roukoz H; Saliba W (January 2007). "Dofetilide: a new class III antiarrhythmic agent". Expert Rev Cardiovasc Ther. 5 (1): 9-19 ... Potassium channel blockers used in the treatment of cardiac arrhythmia are classified as class III antiarrhythmic agents. Class ...
Several patents relate to the use of bispidine ligands for their antiarrhythmic and analgesic activity. It has been also found ... 5. Antiarrhythmic Activity of Selected , '-Disubstituted Bispidines". J. Med. Chem. 20 (12): 1668-1671. doi:10.1021/jm00222a026 ...
It has also been shown as a side effect of certain anti-arrhythmic medications, such as sotalol, procainamide, quinidine, ... Lenz T. L.; Hilleman D. E. (July 2000). "Dofetilide, a New Class III Antiarrhythmic Agent". Pharmacotherapy. 20 (7): 776-86. ... of patients who receive QT-prolonging antiarrhythmic drugs. Most episodes will revert spontaneously to a normal sinus rhythm. ...
It is a class III antiarrhythmic drug. In the United States, the FDA approved label includes a claim for reducing ... Dronedarone is a non-iodinated class III anti-arrhythmic drug which helps patients return to normal sinus rhythm. This ... The drug also appears to exhibit activity in each of the 4 Vaughan-Williams antiarrhythmic classes. Dronedarone is less ... Dronedarone displays amiodarone-like class III antiarrhythmic activity in vitro and in clinical trials. ...
It is a sodium channel blocker and therefore classified as a Class 1a anti-arrhythmic agent. Disopyramide has a negative ... Another concern about disopyramide has been the hypothetical potential for inducing sudden death from its type 1 anti-arrhythmic ... Disopyramide (INN, trade names Norpace and Rythmodan) is an antiarrhythmic medication used in the treatment of ventricular ... Kim, S. Y.; Benowitz, N. L. (1990). "Poisoning due to class IA antiarrhythmic drugs. Quinidine, procainamide and disopyramide ...
... is an antiarrhythmic medication used to treat and prevent a number of types of irregular heartbeats. This includes ... It is a class III antiarrhythmic medication. It works partly by increasing the time before a heart cell can contract again. ... with polymorphic ventricular tachycardia as it is associated with a prolonged QT interval which will be made worse with anti-arrhythmic ...
The class I antiarrhythmic agents interfere with the sodium channel. Class I agents are grouped by what effect they have on the ... Antiarrhythmic agents, also known as cardiac dysrhythmia medications, are a group of pharmaceuticals that are used to suppress ... Magnesium sulfate, an antiarrhythmic drug, but only against very specific arrhythmias which has been used for torsades de ... Common anti-arrhythmic drugs under the modernized classification according to Lei et al. 2018. Cardiac Arrhythmia Suppression ...
Novel Therapeutic Targets for Antiarrhythmic Drugs is a book edited by George Billman and published by John Wiley and Sons in ... Peter R. Kowey (2011). "Book Review: Novel Therapeutic Targets for Antiarrhythmic Drugs". Circulation. 123: e241-e242. doi: ... Mehanna agreed that Novel Therapeutic Targets for Antiarrhythmic Drugs did not adequately cover clinical aspects of drug ... "Description of Novel Therapeutic Targets for Antiarrhythmic Drugs". John Wiley and Sons. Retrieved December 11, 2014. CS1 maint ...
Review the various types of antiarrhythmic agents used in the treatment of atrial fibrillation in this primer. How should the ... However, selection of antiarrhythmic drugs should be based on underlying heart disease and comorbidities, due to drug ... Table 2. Settings for Cautious Use of Antiarrhythmic Agents Drug Name. Settings for Exclusion or Cautious Use. ... Table 3. Selected Drug Interactions With Antiarrhythmic Agents Drug Name. Selected Drug Interactions. ...
Antiarrhythmic Drugs. Class Summary. There is general consensus that certain drugs can be potentially antiarrhythmic in Brugada ... of long-term therapeutic treatment in an experienced medical center can practitioners consider the use of antiarrhythmics for ...
Use of antiarrhythmic agents other than digoxin for the long-term suppression of atrial flutter in sinus node disease (a ... Antiarrhythmic agents. Class Summary. These agents alter the electrophysiologic mechanisms responsible for arrhythmia. ... This recommendation has gradually broadened to encompass other antiarrhythmic agents in patients with other types of repaired ... Sotalol is a class III antiarrhythmic agent that blocks potassium channels, prolongs action potential duration, and lengthens ...
Local anesthetic antiarrhythmic drugs block Na+ channels and have important clinical uses. However, the molecular mechanism by ... Sodium channel selectivity filter regulates antiarrhythmic drug binding. Akihiko Sunami, Samuel C. Dudley Jr., and Harry A. ... Our findings show that the selectivity filter of Na+ channel is close to bound local anesthetic antiarrhythmic drug and that it ... Sodium channel selectivity filter regulates antiarrhythmic drug binding Message Subject (Your Name) has sent you a message from ...
Noun 1. antiarrhythmic medication - a drug used to treat an abnormal heart rhythm antiarrhythmic, antiarrhythmic drug ... antiarrhythmic medication synonyms, antiarrhythmic medication pronunciation, antiarrhythmic medication translation, English ... antiarrhythmic medication. Also found in: Thesaurus.. Related to antiarrhythmic medication: Antiarrhythmic drugs, amiodarone, ... antiarrhythmic, antiarrhythmic drug. amiodarone, Cordarone - an antiarrhythmic drug (trade name Cordarone) that has potentially ...
Since most of the toxicity associated with class 1B antiarrhythmic drugs is dose-related, this review examines adverse effects ... Denaro, C.P., Benowitz, N.L. Poisoning Due to Class 1B Antiarrhythmic Drugs. Med Toxicol Adverse Drug Exp 4, 412-428 (1989). ... Since most of the toxicity associated with class 1B antiarrhythmic drugs is dose-related, this review examines adverse effects ... Antiarrhythmic efficacy, pharmacokinetics and clinical safety of tocainide in convalescent myocardial infarction patients. ...
... nor can any single animal model alone predict antiarrhythmic... ... many animal models are useful for evaluating new antiarrhythmic ... Left Anterior Descend Ventricular Fibrillation Antiarrhythmic Drug Antiarrhythmic Agent Ventricular Tachyarrhythmia These ... In: Clinical Pharmacology of Antiarrhythmic Therapy. Ed. Lucchesi, BR, Dingell, JV and Schwarz RP Jr. Raven Press, N.Y. pp. 31- ... Moore E.N., Spear J.F. (1985) What Animal Models are Useful in Selecting New Antiarrhythmic Drugs?. In: Morganroth J., Moore E. ...
Find antiarrhythmic medications information, treatments for antiarrhythmic medications and antiarrhythmic medications symptoms. ... MedHelps antiarrhythmic medications Center for Information, Symptoms, Resources, Treatments and Tools for antiarrhythmic ...
Can you name the Antiarrhythmics? Test your knowledge on this science quiz to see how you do and compare your score to others. ...
The anti-arrhythmic CCM device 30 includes an anti-arrhythmic therapy unit 38 and an a CCM unit 40. The anti-arrhythmic therapy ... The anti-arrhythmic therapy unit 68 may be any type of device or unit known in the art for delivering one or more anti- ... The anti-arrhythmic CCM device 30 also includes a power source 165 for providing power to the various components of the anti- ... an anti-arrhythmic module 50 is illustrated which is integrated within a CCM anti-arrhythmic device 51 (only a part of the ...
Antiarrhythmics are a type of heart medication that prevent and treat abnormal heartbeats. Learn more about antiarrhythmics ... Antiarrhythmics slow down the electrical impulses in your heart so it can beat regularly again.. Antiarrhythmics can also help ... Antiarrhythmic drugs may be prescribed if your heart beats too quickly. Antiarrhythmics include several classes of drugs which ... What are antiarrhythmics?. Antiarrhythmic medications prevent and treat abnormal heartbeats (arrhythmias). Problems with your ...
The antiarrhythmic and anticonvulsant effects of dietary N-3 fatty acids.. Leaf A1, Kang JX, Xiao YF, Billman GE, Voskuyl RA. ... It has been shown in animals and probably in humans, that n-3 polyunsaturated fatty acids (PUFAs) are antiarrhythmic. We report ... appear at present to be the probable major antiarrhythmic mechanism of the PUFAs. ... recent studies on the antiarrhythmic actions of PUFAs. The PUFAs stabilize the electrical activity of isolated cardiac myocytes ...
... a new potent class I antiarrhythmic agent, was given to 152 patients (46 orally and 106 intravenously) over a period of 22 ... Proarrhythmic effects of the new antiarrhythmic agent flecainide acetate Am Heart J. 1984 Feb;107(2):222-8. doi: 10.1016/0002- ... Flecainide acetate, a new potent class I antiarrhythmic agent, was given to 152 patients (46 orally and 106 intravenously) over ... Two patients who developed ventricular arrhythmias were taking other antiarrhythmic agents, and in this series proarrhythmic ...
... antiarrhythmic, proarrhythmic or both?. Download Prime PubMed App to iPhone, iPad, or Android ... von Schacky C. Omega-3 Fatty Acids: Antiarrhythmic, Proarrhythmic or Both. Curr Opin Clin Nutr Metab Care. 2008;11(2):94-9. ... "Omega-3 Fatty Acids: Antiarrhythmic, Proarrhythmic or Both?" Current Opinion in Clinical Nutrition and Metabolic Care, vol. 11 ... von Schacky C. Omega-3 fatty acids: antiarrhythmic, proarrhythmic or both? Curr Opin Clin Nutr Metab Care. 2008;11(2):94-9. ...
Alteration of defibrillation threshold by antiarrhythmic drugs. a theoretical framework. BABBS, CHARLES F. MD, PHD ... Alteration of defibrillation threshold by antiarrhythmic drugsa theoretical framework Critical Care Medicine9(5):362-363, May ...
Rapid anti-arrhythmic action was achieved in six acute cases with 1.0-1.5 mg propafenon per kg body weight by quick infusion, ... Propafenon, at an initial oral dose of 900 mg, proved an effective anti-arrhythmic drug in 34 patients with frequent ...
Antiarrhythmics, Inotropes, and Vasopressors: 10.4018/978-1-4666-8603-8.ch010: Arrhythmias, low cardiac output syndromes, and ... Antiarrhythmic Agents. Antiarrhythmic drugs exert their action by blocking sodium, potassium or calcium. They are classified as ... "Antiarrhythmics, Inotropes, and Vasopressors." In Modern Concepts and Practices in Cardiothoracic Critical Care, ed. Adam S. ... "Antiarrhythmics, Inotropes, and Vasopressors." Modern Concepts and Practices in Cardiothoracic Critical Care. IGI Global, 2015 ...
"This is the first time anyone has shown that there is a differential response to antiarrhythmic drugs for AFib," pointed out ... but how and why obesity affects response to antiarrhythmic drugs (AADs) remains unclear.. The report published in JAMA ... of AF compared with those without obesity who received sodium channel blocker antiarrhythmic drugs (6%). Both groups had ...
34 ANTIARRHYTHMICS. Class Ia, Ib, Ic, II, III and IV. Brand. Generic. ...
Purchase Advances in Antiarrhythmic Drug Therapy, An Issue of Cardiac Electrophysiology Clinics, Volume 2-3 - 1st Edition. ... Advances in Antiarrhythmic Drug Therapy, An Issue of Cardiac Electrophysiology Clinics, Volume 2-3 1st Edition. ... Antiarrhythmic agents, which are pharmaceutical agents used to suppress fast rhythms of the heart (cardiac arrhythmias), ...
AntiarrhythmicsAntiarrhythmics are drugs that help control the heart rate and rhythm. They do this by either suppressing the ... Antiarrhythmics are drugs that help control the heart rate and rhythm. They do this by either suppressing the activity of ... Antiarrhythmics. Please note: reference image is displayed in place of Flash media. ... Antiarrhythmics include several classes of drugs such as sodium channel blockers, beta-blockers, potassium channel blockers, ...
Studies the effects of antiarrhythmic agents on cardiac function. Membrane depressant agents; Cardiac effects of antiarrhythmic ... Determination of the drug levels following the administration of antiarrhythmic agent; Implications of antiarrhythmic agents ... PAPAVERINE AS AN ANTIARRHYTHMIC AGENT. Whipple, Gerald H. // Angiology;Nov1977, Vol. 28 Issue 11, p737 Suggests a chain of ... Examines the effectiveness of Norpace therapy among patients who had been on antiarrhythmic agents. Indications of toxicity in ...
... Curr Med Chem. 2011;18 ... Suppression of IKr is the common mechanism of action of all class III antiarrhythmics, causing prolongation of the refractory ... Therefore, a new potential anti-arrhythmic strategy, based on augmentation of the repolarization reserve, has been emerged. ... Although the multiple ion channel activity of NS1643 may carry proarrhythmic risk, the rationale of antiarrhythmic strategy ...
Electrophysiological Effects of Ranolazine, a Novel Antianginal Agent With Antiarrhythmic Properties. Charles Antzelevitch, ... Amiodarone is a potent antiarrhythmic agent used in the management of both atrial and ventricular arrhythmias. In addition to ... Assessment of reverse use-dependent blocking actions of class III antiarrhythmic drugs by 24-hour Holter electrocardiography. J ... The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report ...
Radiofrequency Ablation (RFA) Versus Antiarrhythmic Drug Treatment in Paroxysmal Atrial Fibrillation (MANTRA-PAF). The safety ... Medical antiarrhythmic treatment is only moderately effective and has the risk of severe side effects. The present study is a ... Radiofrequency Ablation (RFA) Versus Antiarrhythmic Drug Treatment in Paroxysmal Atrial Fibrillation. Official Title ICMJE ... Medical Antiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrillation: A Randomized Prospective ...
Antiarrhythmic Effect of E3G on SCN5A-Related Cardiac Syndrome, MEPPC, and EPVT. To investigate the potential antiarrhythmic ... including antiarrhythmics. Nevertheless, antiarrhythmic drugs are usually accompanied by some serious side effects. Thus, ... Antiarrhythmic Effect of E3G on the MEPPC and EPVT Syndromes. By implementing the experimental functional effects of E3G on the ... In order to evaluate the possible antiarrhythmic effect of E3G in the sitting of MEPPC and EPVT cardiac disorders, the ...
Class III antiarrhythmic agents establish a chemical conversion to sinus rhythm. Intravenous amiodarone has been shown to slow ... encoded search term (What is the role of class III antiarrhythmics in the treatment of atrial flutter?) and What is the role of ... What is the role of class III antiarrhythmics in the treatment of atrial flutter?. Updated: Nov 09, 2018 ... class III antiarrhythmics in the treatment of atrial flutter? What to Read Next on Medscape. Related Conditions and Diseases. * ...
  • Antiarrhythmic agents, also known as cardiac dysrhythmia medications, are a group of pharmaceuticals that are used to suppress abnormal rhythms of the heart (cardiac arrhythmias), such as atrial fibrillation, atrial flutter, ventricular tachycardia, and ventricular fibrillation. (wikipedia.org)
  • Overall, he recommended the book, calling it "a worthwhile addition to the literature on cardiac arrhythmia and antiarrhythmic drugs. (wikipedia.org)
  • Magnesium sulfate, an antiarrhythmic drug, but only against very specific arrhythmias which has been used for torsades de pointes. (wikipedia.org)
  • In a review for ChemMedChem, medicinal chemistry professor Ahmed S. Mehanna agreed that Novel Therapeutic Targets for Antiarrhythmic Drugs did not adequately cover clinical aspects of drug development. (wikipedia.org)
  • When you are on this pill avoid the intake of type 1A & 3 Antiarrhythmic such as Quinidine, Procainamide, Sotalol, Amiodarone, and alpha blockers. (safegenericpharmacy.com)
  • Examples of affected drugs include antiarrhythmic drugs (such as propafenone, flecainide, quinidine) antipsychotics (such as thioridazine) tricyclic antidepressants (such as desipramine, imipramine) among others. (gayweddingsmag.com)
  • Domestic pigeons originally lived history the term manifest antiarrhythmic drugs to facilitate that has truly give. (okphotostudio.com)
  • It has been reported to manifest antidepressant, anticonvulsant and antiarrhythmic acts as well as to possess antioxidant and lipid peroxidation activities. (totalayurvedacare.com)
  • blockers and other antiarrhythmics. (medicscientist.com)
  • This improvement may be explained partly through the increased use of ACEI/ARB and beta blockers and a declining use of antiarrhythmics. (charitableaction.com)
  • An antiarrhythmic Ia class drug, a blocker of the "fast" Na+ channels. (pharmasite.top)
  • Only for treatment of the following documented life-threatening recurrent ventricular arrhythmias that do not respond to other antiarrhythmics or when alternative agents are not tolerated: Recurrent ventricular fibrillation, recurrent hemodynamically unstable ventricular tachycardia. (nursingpath.in)